Investor Arkin Moshe
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Arkin Moshe . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2025-06-12 13D/A SLGL / Sol-Gel Technologies Ltd. 1,950,113
2025-04-30 13D/A SLGL / Sol-Gel Technologies Ltd. 18,449,907
2025-03-06 13G ODYS / Odysight.ai Inc. 7,926,329
2024-08-26 13G EIGR / Eiger BioPharmaceuticals, Inc. 53,071
2024-07-01 13D/A EIGR / Eiger BioPharmaceuticals, Inc. 4,481,126 53,071
2024-04-08 13D/A SLGL / Sol-Gel Technologies Ltd.
2024-02-22 13D/A URGN / UroGen Pharma Ltd.
2023-12-04 13D/A EIGR / Eiger BioPharmaceuticals, Inc. 4,482,126 4,481,126
2023-11-24 13D EIGR / Eiger BioPharmaceuticals, Inc. 4,482,126 4,482,126
2023-04-18 13G/A EIGR / Eiger BioPharmaceuticals, Inc. 2,713,002 4,482,126
2023-03-20 13D/A SLGL / Sol-Gel Technologies Ltd.
2023-02-02 13G/A EIGR / Eiger BioPharmaceuticals, Inc. 1,826,226 2,713,002
2023-02-02 13G/A KROS / Keros Therapeutics, Inc. 1,812,315 1,371,074
2023-02-02 13G/A ONCR / Oncorus, Inc. 1,467,089 2,508,481
2022-04-12 13G/A KROS / Keros Therapeutics, Inc. 1,812,315 1,812,315
2022-04-11 13G KROS / Keros Therapeutics, Inc. 2,036,140 1,812,315
2022-03-08 13G EIGR / Eiger BioPharmaceuticals, Inc. 1,826,226
2021-12-02 13G ONCR / Oncorus, Inc. 1,467,089
2021-05-10 13D HOWL / Werewolf Therapeutics, Inc.
2020-12-17 13D/A KROS / Keros Therapeutics, Inc. 2,036,140 2,036,140
2020-11-25 13D/A KROS / Keros Therapeutics, Inc. 2,036,140 2,036,140
2020-04-20 13D KROS / Keros Therapeutics, Inc. 2,036,140
2020-04-20 13D/A SLGL / Sol-Gel Technologies Ltd.
2020-02-12 13D/A URGN / UroGen Pharma Ltd.
2020-02-06 13G CNCE / Concert Pharmaceuticals Inc 1,572,394
2019-12-19 13D/A ACRS / Aclaris Therapeutics, Inc. 2,683,240 1,967,082
2019-11-21 13D/A ACRS / Aclaris Therapeutics, Inc. 3,319,750 2,683,240
2019-10-15 13D ACRS / Aclaris Therapeutics, Inc. 3,319,750
2019-08-21 13D/A SLGL / Sol-Gel Technologies Ltd.
2019-06-03 13D/A URGN / UroGen Pharma Ltd.
2018-09-13 13G/A IVTY / Invuity, Inc. 1,490,111 0
2018-05-24 13G IVTY / Invuity, Inc. 1,490,111
2018-05-24 13D URGN / UroGen Pharma Ltd.
2018-02-12 13D SLGL / Sol-Gel Technologies Ltd.
2017-05-30 13D URGN / UroGen Pharma Ltd.
2014-02-18 13G/A NGSX / NeurogesX, Inc. 0
2012-03-02 13D/A PRGO / Perrigo Company plc 4,531,281
2012-01-18 13G/A NGSX / NeurogesX, Inc. 2,619,307